Eumorphia G. Konstantakou
National and Kapodistrian University of Athens
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eumorphia G. Konstantakou.
Cancer Cell International | 2013
Panagiotis K. Karkoulis; Dimitrios J. Stravopodis; Eumorphia G. Konstantakou; Gerassimos E. Voutsinas
BackgroundGeldanamycin (GA) can be considered a relatively new component with a promising mode of action against human malignancies. It specifically targets heat shock protein 90 (Hsp90) and interferes with its function as a molecular chaperone.MethodsIn this study, we have investigated the effects of geldanamycin on the regulation of Hsp90-dependent oncogenic signaling pathways directly implicated in cell cycle progression, survival and motility of human urinary bladder cancer cells. In order to assess the biological outcome of Hsp90 inhibition on RT4 (grade I) and T24 (grade III) human urinary bladder cancer cell lines, we applied MTT assay, FACS analysis, Western blotting, semi-quantitative (sq) RT-PCR, electrophoretic mobility shift assay (EMSA), immunofluorescence and scratch-wound assay.ResultsWe have herein demonstrated that, upon geldanamycin treatment, bladder cancer cells are prominently arrested in the G1 phase of cell cycle and eventually undergo programmed cell death via combined activation of apoptosis and autophagy. Furthermore, geldanamycin administration proved to induce prominent downregulation of several Hsp90 protein clients and downstream effectors, such as membrane receptors (IGF-IR and c-Met), protein kinases (Akt, IKKα, IKKβ and Erk1/2) and transcription factors (FOXOs and NF-κΒ), therefore resulting in the impairment of proliferative -oncogenic- signaling and reduction of cell motility.ConclusionsIn toto, we have evinced the dose-dependent and cell line-specific actions of geldanamycin on cell cycle progression, survival and motility of human bladder cancer cells, due to downregulation of critical Hsp90 clients and subsequent disruption of signaling -oncogenic- integrity.
Journal of Cancer Research and Clinical Oncology | 2011
Dimitrios J. Stravopodis; Panagiotis K. Karkoulis; Eumorphia G. Konstantakou; Sophia Melachroinou; Angeliki Thanasopoulou; Gerasimos Aravantinos; Lukas H. Margaritis; Ema Anastasiadou; Gerassimos E. Voutsinas
PurposeIn search for more effective clinical protocols, the antimetabolite drug 5-fluorouracil (5-FU) has been successfully included in new regimens of bladder cancer combination chemotherapy. In the present study, we have investigated the effects of 5-FU treatment on apoptosis induction in wild-type and mutant p53 urinary bladder cancer cells.MethodsWe have used MTT-based assays, FACS analysis, Western blotting and semi-quantitative RT-PCR in RT4 and RT112 (grade I, wild-type p53), as well as in T24 (grade III, mutant p53) and TCCSUP (grade IV, mutant p53) human urinary bladder cancer cell lines.ResultsIn the urothelial bladder cancer cell lines RT4 and T24, 5-FU-induced TS inhibition proved to be associated with cell type-dependent (a) sensitivity to the drug, (b) Caspase-mediated apoptosis, (c) p53 stabilization and activation, as well as Rb phosphorylation and E2F1 expression and (d) transcriptional regulation of p53 target genes and their cognate proteins, while an E2F-dependent transcriptional network did not seem to be critically engaged in such type of responses.ConclusionsWe have shown that in the wild-type p53 context of RT4 cells, 5-FU-triggered apoptosis was prominently efficient and mainly regulated by p53-dependent mechanisms, whereas the mutant p53 environment of T24 cells was able to provide notable levels of resistance to apoptosis, basically ascribed to E2F-independent, and still unidentified, pathways. Nevertheless, the differential vulnerability of RT4 and T24 cells to 5-FU administration could also be associated with cell-type-specific transcriptional expression patterns of certain genes critically involved in 5-FU metabolism.
Molecular Cancer | 2015
Eumorphia G. Konstantakou; Gerassimos E. Voutsinas; Athanassios D. Velentzas; Aggeliki-Stefania Basogianni; Efthimios Paronis; Evangelos Balafas; Nikolaos Kostomitsopoulos; Konstantinos Syrigos; Ema Anastasiadou; Dimitrios J. Stravopodis
BackgroundUrinary bladder cancer is one of the most fatal and expensive diseases of industrialized world. Despite the strenuous efforts, no seminal advances have been achieved for its clinical management. Given the importance of metabolic reprogramming in cancer cell survival and growth, we have herein employed 3-BrPA, a halogenated derivative of pyruvate and historically considered inhibitor of glycolysis, to eliminate bladder cancer cells with highly oncogenic molecular signatures.MethodsBladder cancer cells were exposed to 3-BrPA in the absence or presence of several specific inhibitors. Cell viability was determined by MTT and flow-cytometry assays; cell death, signaling activity and metabolic integrity by Western blotting and immunofluorescence; mutant-gene profiling by DNA sequencing; and gene expression by RT-sqPCR.Results3-BrPA could activate dose-dependent apoptosis (type 1 PCD) and regulated necrosis (type 3 PCD) of T24 (grade III; H-RasG12V; p53ΔY126), but not RT4 (grade I), cells, with PARP, MLKL, Drp1 and Nec-7-targeted components critically orchestrating necrotic death. However, similarly to RIPK1 and CypD, p53 presented with non-essential contribution to 3-BrPA-induced cellular collapse, while reactivation of mutant p53 with PRIMA-1 resulted in strong synergism of the two agents. Given the reduced expression of MPC components (likely imposing mitochondrial dysfunction) in T24 cells, the suppression of constitutive autophagy (required by cells carrying oncogenic Ras; also, type 2 PCD) and derangement of glucose-homeostasis determinants by 3-BrPA critically contribute to drug-directed depletion of ATP cellular stores. This bioenergetic crisis is translated to severe dysregulation of Akt/FoxO/GSK-3, mTOR/S6, AMPK and MAPK (p44/42, p38 and SAPK/JNK) signaling pathways in 3-BrPA-treated T24 cells. Sensitivity to 3-BrPA (and tolerance to glucose deprivation) does not rely on B-RafV600E or K-RasG13D mutant oncogenic proteins, but partly depends on aberrant signaling activities of Akt, MAPK and AMPK kinases. Interestingly, MCT1- and macropinocytosis-mediated influx of 3-BrPA in T24 represents the principal mechanism that regulates cellular responsiveness to the drug. Besides its capacity to affect transcription in gene-dependent manner, 3-BrPA can also induce GLUT4-specific splicing silencing in both sensitive and resistant cells, thus dictating alternative routes of drug trafficking.ConclusionsAltogether, it seems that 3-BrPA represents a promising agent for bladder cancer targeted therapy.
Scientific Reports | 2016
Athanassios D. Velentzas; Panagiotis D. Velentzas; Niki E. Sagioglou; Eumorphia G. Konstantakou; Athanasios Anagnostopoulos; Maria M. Tsioka; Vassiliki E. Mpakou; Z. Kollia; Christos Consoulas; Lukas H. Margaritis; Issidora S. Papassideri; George Th. Tsangaris; E. Sarantopoulou; A.C. Cefalas; Dimitrios J. Stravopodis
Drosophila chorion represents a model biological system for the in vivo study of gene activity, epithelial development, extracellular-matrix assembly and morphogenetic-patterning control. It is produced during the late stages of oogenesis by epithelial follicle cells and develops into a highly organized multi-layered structure that exhibits regional specialization and radial complexity. Among the six major proteins involved in chorion’s formation, the s36 and s38 ones are synthesized first and regulated in a cell type-specific and developmental stage-dependent manner. In our study, an RNAi-mediated silencing of s36 chorionic-gene expression specifically in the follicle-cell compartment of Drosophila ovary unearths the essential, and far from redundant, role of s36 protein in patterning establishment of chorion’s regional specialization and radial complexity. Without perturbing the developmental courses of follicle- and nurse-cell clusters, the absence of s36 not only promotes chorion’s fragility but also induces severe structural irregularities on chorion’s surface and entirely impairs fly’s fertility. Moreover, we herein unveil a novel function of s36 chorionic protein in the regulation of number and morphogenetic integrity of dorsal appendages in follicles sporadically undergoing aged fly-dependent stress.
PLOS ONE | 2017
Eumorphia G. Konstantakou; Athanassios D. Velentzas; Athanasios Anagnostopoulos; Zoi I. Litou; Ourania A. Konstandi; Aikaterini F. Giannopoulou; Ema Anastasiadou; Gerassimos E. Voutsinas; George Th. Tsangaris; Dimitrios J. Stravopodis
Cutaneous melanoma is a malignant tumor of skin melanocytes that are pigment-producing cells located in the basal layer (stratum basale) of epidermis. Accumulation of genetic mutations within their oncogenes or tumor-suppressor genes compels melanocytes to aberrant proliferation and spread to distant organs of the body, thereby resulting in severe and/or lethal malignancy. Metastatic melanoma’s heavy mutational load, molecular heterogeneity and resistance to therapy necessitate the development of novel biomarkers and drug-based protocols that target key proteins involved in perpetuation of the disease. To this direction, we have herein employed a nano liquid chromatography-tandem mass spectrometry (nLC-MS/MS) proteomics technology to profile the deep-proteome landscape of WM-266-4 human metastatic melanoma cells. Our advanced melanoma-specific catalogue proved to contain 6,681 unique proteins, which likely constitute the hitherto largest single cell-line-derived proteomic collection of the disease. Through engagement of UNIPROT, DAVID, KEGG, PANTHER, INTACT, CYTOSCAPE, dbEMT and GAD bioinformatics resources, WM-266-4 melanoma proteins were categorized according to their sub-cellular compartmentalization, function and tumorigenicity, and successfully reassembled in molecular networks and interactomes. The obtained data dictate the presence of plastically inter-converted sub-populations of non-cancer and cancer stem cells, and also indicate the oncoproteomic resemblance of melanoma to glioma and lung cancer. Intriguingly, WM-266-4 cells seem to be subjected to both epithelial-to-mesenchymal (EMT) and mesenchymal-to-epithelial (MET) programs, with 1433G and ADT3 proteins being identified in the EMT/MET molecular interface. Oncogenic addiction of WM-266-4 cells to autocrine/paracrine signaling of IL17-, DLL3-, FGF(2/13)- and OSTP-dependent sub-routines suggests their critical contribution to the metastatic melanoma chemotherapeutic refractoriness. Interestingly, the 1433G family member that is shared between the BRAF- and EMT/MET-specific interactomes likely emerges as a novel and promising druggable target for the malignancy. Derailed proliferation and metastatic capacity of WM-266-4 cells could also derive from their metabolic addiction to pathways associated with glutamate/ammonia, propanoate and sulfur homeostasis, whose successful targeting may prove beneficial for advanced melanoma-affected patients.
International Journal of Oncology | 2009
Eumorphia G. Konstantakou; Gerassimos E. Voutsinas; Panagiotis K. Karkoulis; Gerasimos Aravantinos; Lukas H. Margaritis; Dimitrios J. Stravopodis
International Journal of Oncology | 1992
Dimitrios J. Stravopodis; Panagiotis K. Karkoulis; Eumorphia G. Konstantakou; Sophia Melachroinou; Antonis D. Lampidonis; Dimitra Anastasiou; Stefanos Kachrilas; Niki Messini-Nikolaki; Issidora S. Papassideri; Gerasimos Aravantinos; Lukas H. Margaritis; Gerassimos E. Voutsinas
Cancer Genomics & Proteomics | 2015
Athanassios D. Velentzas; Athanasios K. Anagnostopoulos; Panagiotis D. Velentzas; Vassiliki E. Mpakou; Niki E. Sagioglou; Maria M. Tsioka; Stamatia Katarachia; Areti K. Manta; Eumorphia G. Konstantakou; Issidora S. Papassideri; George Th. Tsangaris; Dimitrios J. Stravopodis
Anticancer Research | 2012
Angeliki Thanasopoulou; Alexandra G. Xanthopoulou; Athanasios Anagnostopoulos; Eumorphia G. Konstantakou; Lukas H. Margaritis; Isidora S. Papassideri; Dimitrios J. Stravopodis; George Th. Tsangaris; Ema Anastasiadou
Advances in Breast Cancer Research | 2013
Ifigeneia Marinou; Sophia Havaki; Nikos Goutas; Dimitrios Vlachodimitropoulos; Georgios Baltatzis; Eumorphia G. Konstantakou; Dimitrios J. Stravopodis; Dimitrios G. Koudoumas; Evangelos Marinos; Mirsini Kouloukoussa